Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

634.O3.8 Myeloproliferative Disorders-Clinical Trials

Monday, December 8, 2008: 3:30 PM-5:30 PM
Gateway Ballroom 104 - South (Moscone Center)
Moderators:
Mark Lawrence Heaney, MD, PhD and Virginia Zaleskas, MD
3:30 PM
A New Prognostic Scoring System for Primary Myelofibrosis Based on a Study of the International Working Group for Myelofibrosis Research and Treatment

Francisco Cervantes, MD1, Brigitte Dupriez, MD2*, Arturo Pereira, MD3*, Francesco Passamonti, MD4*, John T Reilly, MD5*, Enrica Morra, MD6*, Alessandro Vannucchi, MD7*, Ruben A. Mesa, MD, FACP8, Jean-Loup Demory, MD9*, Giovanni Barosi, MD10*, Elisa Rumi, MD4* and Ayalew Tefferi, MD11

1Dept. of Hematology, Hospital Clinic, Barcelona, Spain
2Hematology Department, Centre Hospitalier Lens, Lens, France
3Hematology Department, Hospital Clinic, Barcelona, Spain
4Hematology Department, Fondazione IRCCS, Istituto Policlinico San Matteo, Pavia, Italy
5Hematology Department, Royal Hallamshire Hospital, Sheffield, United Kingdom
6Hematology Department, Universita Milano-Niguarda, Milan, Italy
7Hematology Department, University of Florence, Florence, Italy
8Mayo Clinic, Rochester, MN
9Hematology Department, Hopital St. Vincent De Paul, Lille, France
10Unit of Clinical Epidemiology, Center for the Study of Myelofibrosis, Istituto Policlinico San Matteo, Pavia, Italy
11Medicine, Division of Hematology, Mayo Clinic Graduate School of Medicine, Rochester, MN

3:45 PM
Pegylated Interferon-ALFA-2A (PEG-IFN-α-2A; PEGASYS ) Therapy Renders High Clinical and Molecular Response Rates in Patients with Essential Thrombocythemia (ET) and Polycythemia VERA (PV)

Alfonso Quintas-Cardama, MD1, Hagop M. Kantarjian, MD2*, Guillermo Garcia-Manero, MD3*, Jorge Cortes, MD4, Marie Ann Richie3*, Gautam Borthakur, MD5 and Srdan Verstovsek4

1Medical Oncology, UT MD Anderson Cancer Center, Houston, TX
2Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
3Leukemia, U.T.M.D. Anderson Cancer Center, Houston, TX
4M.D. Anderson Cancer Center, Houston, TX
5Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX

4:00 PM
Can Peg-Interferon (IFN) α-2a Eradicate JAK2V617F-Positive Bone Marrow Progenitors in Polycythemia Vera (PV)?

Jean-Jacques Kiladjian1*, Sabrina Dupont2*, Bruno Cassinat3*, Aline Massé2*, William Vainchenker2, Christine Chomienne4*, François Delhommeau5* and Pierre Fenaux1

1Hématologie Clinique, Assistance Publique - Hôpitaux de Paris, Hôpital Avicenne; Paris 13 University, Bobigny, France
2INSERM U790, Institut Gustave Roussy, Villejuif, France
3Unité de Biologie Cellulaire, Assistance Publique - Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France
4Institut Universitaire d'Hematologie, Inserm U718, Paris, France
5Laboratoire d'Hématologie, Assistance Publique - Hôpitaux de Paris, Hôpital Saint-Antoine; Université Paris 6 Pierre et Marie Curie, Paris, France

4:15 PM
Major Hematological Response Is the Main Factor for Achieving a Major Molecular Response in JAK2V617F-Positive Essential Thrombocythemia and Polycythemia Vera Patients Treated with Hydroxyurea

C. Besses*, A Álvarez-Larrán*, L Martínez-Avilés*, R Longarón*, S Serrano* and B Bellosillo*

Hematology, Hospital del Mar, Barcelona, Spain

4:30 PM
Final Results of the ANAHYDRET-Study: Non-Inferiority of Anagrelide Compared to Hydroxyurea in Newly Diagnosed WHO-Essential Thrombocythemia Patients

Heinz Gisslinger1, Mirjana Gotic2*, Jerzy Holowiecki3, Miroslav Penka4*, Juergen Thiele5*, Hans Michael Kvasnicka5*, Robert Kralovics6 and Petro E. Petrides7*

1Department of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria
2Institute of Hematology, Belgrade, Serbia
3Silesian Medical University, Katowice, Poland
4Department of Clinical Hematology, Masaryk University Faculty Hospital, Brno, Czech Republic
5Insitute of Pathology, University of Cologne, Cologne, Germany
6Center for Molecular Medicine, Austrian Academy of Sciences, Vienna, Austria
7Hematology Oncology Center, Munich, Germany

4:45 PM
Combined Therapy with Lenalidomide and Prednisone Renders Durable Clinical, Histopathological, and Molecular Responses in Patients with Myelofibrosis

Alfonso Quintas-Cardama, MD1, Hagop M. Kantarjian, MD2*, Deborah A. Thomas, MD2, Jorge Cortes, MD3, Farhad Ravandi, MBBS4, Stefan Faderl, MD3, Guillermo Garcia-Manero, MD5, Gautam Borthakur, MD6, Neda Bell7*, Catriona Byrne7* and Srdan Verstovsek3

1Medical Oncology, UT MD Anderson Cancer Center, Houston, TX
2Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
3M.D. Anderson Cancer Center, Houston, TX
4Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX
5Leukemia, U.T. M.D. Anderson Cancer Center, Houston, TX
6Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX
7Celgene Corporation, Summit, NJ

5:00 PM
Pomalidomide Therapy in Anemic Patients with Myelofibrosis: Results from a Phase-2 Randomized Multicenter Study

Ayalew Tefferi, MD1, Srdan Verstovsek2, Giani Barosi3*, Francesco Passamonti, MD4*, Gail J. Roboz, MD5, Heinz Gisslinger6*, Ronald Paquette, MD7, Francisco Cervantes, MD8, Candido E. Rivera, MD9, H. Joachim Deeg10, Juergen Thiele11*, Hans Michael Kvasnicka11*, James W. Vardiman, MD12, B. Nebiyou Bekele, PhD13*, Ruben A. Mesa, MD, FACP14, Robert P Gale15* and Hagop M Kantarjian16

1Medicine, Division of Hematology, Mayo Clinic Graduate School of Medicine, Rochester, MN
2M.D. Anderson Cancer Center, Houston, TX
3IRCCS Policlinico San Matteo, Pavia, Italy
4Department of Hematology Oncology, University of Pavia & Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
5Medicine, Weill Cornell Medical College, New York, NY
6Department of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria
7Ronald Reagan UCLA Medical Center, Los Angeles, CA
8Dept. of Hematology, Hospital Clinic, Barcelona, Spain
9Mayo Clinic, Jacksonville, FL
10Fred Hutchinson Cancer Research Center, Seattle, WA
11Insitute of Pathology, University of Cologne, Cologne, Germany
12University of Chicago, Chicago, IL
13Department of Biostatistics, University of Texas M.D. Anderson Cancer Center, Houston, TX
14Mayo Clinic, Rochester, MN
15Celgene Corporation, Summit, NJ
16The University of Texas M. D. Anderson Cancer Center, Houston, TX

5:15 PM
Retrospective Evaluation of 90 Children with Essential Thrombocytemia: The AIEOP Experience

Maria Caterina Putti, MD1*, Fiorina Giona, MD2*, Caterina Consarino, MD3*, Gian Mario Fiori, MD4*, Paola Giordano, MD5*, Saverio Ladogana, MD6*, Momcilo Jankovic, MD7*, Concetta Micalizzi, MD8*, Andrea Pession, MD, PhD9, Paolo Pierani, MD10*, Ugo Ramenghi, MD11, Margherita Scapin, PhD12*, Luciana Teofili, MD13*, Fabio Tucci, MD14*, Katia Tettoni, MD15*, Andrea Giulio Zanazzo16* and Maria Luigia Randi, MD17*

1Pediatric Hematology Oncology, University of Padova, Padova, Italy
2Division of Haematology, La Sapienza University, Rome, Italy
3Pediatric Hematology Oncology, Az. Osp. “Pugliese-Ciaccio”
4Pediatric Hematology Oncology, Ospedale Regionale per le Microcitemie, Cagliari, Italy
5Dipartimento Età Evolutiva, University of Bari, Bari, Italy
6Pediatric Hematology Oncology, Casa Sollievo della Sofferenza Hospital, San Goivanni Rotondo, Italy
7Pediatric Hematology, Ospedale S. Gerardo, University of Milano, Monza, Italy
8Department of Paediatric Haematology and Oncology, Giannina Gaslini Institute, Genova, Italy
9Oncologia-Ematologia Pediatrica, Santorsola-Malpicitci, Bologna, Italy
10Children's Hospital G.Salesi, Pediatric Hematology Oncology, Ancona, Italy
11Pediatric Dept., University of Torino, Torino, Italy
12Department of Medical and Surgical Science, University of Padua, Padova, Italy
13Department of Haematology, Catholic University, Rome, Hungary
14Pediatric Hematology Oncology, A.O. Meyer, Firenze, Italy
15Pediatric Hematology Oncology, Pediatric Hospital, Brescia, Italy
16Istituto Burlo Garofalo, Pediatric Hematology Oncology, Trieste
17University Unit, Padova, Italy

*signifies non-member of ASH